全文获取类型
收费全文 | 1877篇 |
免费 | 132篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 26篇 |
妇产科学 | 38篇 |
基础医学 | 278篇 |
口腔科学 | 13篇 |
临床医学 | 162篇 |
内科学 | 519篇 |
皮肤病学 | 12篇 |
神经病学 | 226篇 |
特种医学 | 40篇 |
外科学 | 248篇 |
综合类 | 10篇 |
预防医学 | 66篇 |
眼科学 | 32篇 |
药学 | 194篇 |
中国医学 | 2篇 |
肿瘤学 | 178篇 |
出版年
2021年 | 13篇 |
2020年 | 20篇 |
2019年 | 18篇 |
2018年 | 35篇 |
2017年 | 32篇 |
2016年 | 30篇 |
2015年 | 39篇 |
2014年 | 66篇 |
2013年 | 73篇 |
2012年 | 144篇 |
2011年 | 142篇 |
2010年 | 91篇 |
2009年 | 63篇 |
2008年 | 101篇 |
2007年 | 128篇 |
2006年 | 116篇 |
2005年 | 142篇 |
2004年 | 108篇 |
2003年 | 114篇 |
2002年 | 87篇 |
2001年 | 23篇 |
2000年 | 17篇 |
1999年 | 31篇 |
1998年 | 25篇 |
1997年 | 19篇 |
1996年 | 12篇 |
1995年 | 20篇 |
1994年 | 17篇 |
1993年 | 16篇 |
1992年 | 14篇 |
1991年 | 22篇 |
1990年 | 13篇 |
1989年 | 8篇 |
1988年 | 14篇 |
1987年 | 17篇 |
1986年 | 15篇 |
1985年 | 12篇 |
1984年 | 13篇 |
1983年 | 15篇 |
1982年 | 12篇 |
1981年 | 10篇 |
1980年 | 9篇 |
1979年 | 10篇 |
1978年 | 16篇 |
1977年 | 6篇 |
1976年 | 6篇 |
1975年 | 8篇 |
1973年 | 11篇 |
1972年 | 7篇 |
1966年 | 6篇 |
排序方式: 共有2054条查询结果,搜索用时 15 毫秒
101.
Otvos L Kovalszky I Riolfi M Ferla R Olah J Sztodola A Nama K Molino A Piubello Q Wade JD Surmacz E 《European journal of cancer (Oxford, England : 1990)》2011,47(10):1578-1584
Triple-negative breast cancers, which represent 10-20% of all mammary tumours, are characterised by the aggressive phenotype, are often found in younger women and have been associated with poor prognosis. Obesity increases the risk for triple-negative breast cancer development. Because triple-negative breast cancer patients are unresponsive to current targeted therapies and other treatment options are only partially effective, new pharmacological modalities are urgently needed. Here we examined if the leptin (obesity hormone) receptor is a viable target for the treatment of this cancer subtype. In human triple-negative breast cancer tissues, the leptin receptor was expressed in 92% (64/69) and leptin in 86% (59/69) of cases. In a model triple-negative breast cancer cell line MDA-MB-231, the leptin receptor antagonist peptide Allo-aca inhibited leptin-induced proliferation at 50 pM concentration. In an MDA-MB-231 orthotopic mouse xenograft model, Allo-aca administered subcutaneously significantly extended the average survival time from 15.4 days (untreated controls) to 24 and 28.1 days at 0.1 and 1 mg/kg/day doses, respectively. In parallel, conventional treatment with 1 mg/kg/day intraperitoneal cisplatin prolonged the average survival time to 18.6 days, while administration of 20 mg/kg/day oral Tamoxifen (negative control) had no significant survival effects relative to controls. In normal CD-1 mice, Allo-aca produced no systemic toxicity up to the highest studied subcutaneous bolus dose of 50 mg/kg, while, as expected, it induced a modest 6-10% body weight increase. Our results indicate that leptin receptor antagonists could become attractive options for triple-negative breast cancer treatment, especially in the obese patient population. 相似文献
102.
Takanori Kitamura Teruaki Fujishita Pius Loetscher Laszlo Revesz Hiroki Hashida Shinae Kizaka-Kondoh Masahiro Aoki Makoto M. Taketo 《Proceedings of the National Academy of Sciences of the United States of America》2010,107(29):13063-13068
Recent reports have suggested critical roles of myeloid cells in tumor invasion and metastasis, although these findings have not led to therapeutics. Using a mouse model for liver dissemination, we show that mouse and human colon cancer cells secrete CC-chemokine ligands CCL9 and CCL15, respectively, and recruit CD34+ Gr-1− immature myeloid cells (iMCs). They express CCL9/15 receptor CCR1 and produce matrix metalloproteinases MMP2 and MMP9. Lack of the Ccr1, Mmp2, or Mmp9 gene in the host dramatically suppresses outgrowths of disseminated tumors in the liver. Importantly, CCR1 antagonist BL5923 blocks the iMC accumulation and metastatic colonization and significantly prolongs the survival of tumor-bearing mice. These results suggest that CCR1 antagonists can provide antimetastatic therapies for patients with disseminated colon cancer in the liver. 相似文献
103.
Csaba Ambrus Miklos Zsolt Molnar Maria Eszter Czira Laszlo Rosivall Istvan Kiss Adam Remport Miklos Szathmari Istvan Mucsi 《International urology and nephrology》2009,41(4):1029-1038
Introduction
Impaired kidney function is common in kidney-transplanted patients and complications of chronic kidney disease (CKD), such as mineral and bone disorders (MBD) are also prevalent in this population. Similarly to other stages of CKD, increasing evidence supports the association between MBD and cardiovascular risk after kidney transplantation as well. Still, little is known about the prevalence, clinical correlates of MBD and its management in transplanted patients. In this study, we aimed to examine the characteristics of MBD and its associations with clinical parameters in a large prevalent cohort of patients after kidney transplantation. 相似文献104.
105.
106.
Cardiovascular disease (CVD) is the leading cause of mortality in the Western world. The effort of research should aim at the primary prevention of CVD. Alongside statin therapy, which is maintained to be an effective method of CVD prevention, there are alternative methods such as vitamin B substitution therapy with folic acid (FA), and vitamins B12 and B6. B‐vitamins may inhibit atherogenesis by decreasing the plasma level of homocysteine (Hcy)—a suspected etiological factor for atherosclerosis—and by other mechanisms, primarily through their antioxidant properties. Although Hcy‐lowering vitamin trials have failed to demonstrate beneficial effects of B‐vitamins in the prevention of CVD, a meta‐analysis and stratification of a number of large vitamin trials have suggested their effectiveness in cardiovascular prevention (CVP) in some aspects. Furthermore, interpretation of the results from these large vitamin trials has been troubled by statin/aspirin therapy, which was applied along with the vitamin substitution, and FA fortification, both of which obscured the separate effects of vitamins in CVP. Recent research results have accentuated a new approach to vitamin therapy for CVP. Studies undertaken with the aim of primary prevention have shown that vitamin B substitution may be effective in the primary prevention of CVD and may also be an option in the secondary prevention of disease if statin therapy is accompanied by serious adverse effects. Further investigations are needed to determine the validity of vitamin substitution therapy before its introduction in the protocol of CVD prevention. 相似文献
107.
CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has therefore been exploited as target for therapeutic antibodies for many years. The improved survival seen in many patients when the antibody-drug conjugate, gemtuzumab ozogamicin, is added to conventional chemotherapy validates this approach. However, many attempts with unconjugated or conjugated antibodies have been unsuccessful, highlighting the challenges of targeting CD33 in AML. With the development of improved immunoconjugates and CD33-directed strategies that harness immune effector cells, therapeutics with enhanced efficacy may soon become available. Toxic effects on normal hematopoietic cells may increase in parallel with this increased efficacy and demand new supportive care measures, including possibly rescue with donor cells, to minimize morbidity and mortality from drug-induced cytopenias and to optimize treatment outcomes with these agents in patients with AML. 相似文献
108.
The lifetime risk of overt hypothyroidism is around 5%, and this disease is usually preceded by subclinical hypothyroidism, which has an even higher prevalence (estimated to be up to 9%). Hypothyroidism has been linked with cardiac dysfunction, atherosclerosis, hypertension and coagulopathy. Intuitively, this increased morbidity is expected to shorten patients' lifespan, but definitive data are lacking on whether either of these hypothyroid states (particularly overt hypothyroidism) increase mortality. Study findings are inconsistent and, overall, the pooled data do not demonstrate increased mortality in patients with either subclinical or overt hypothyroidism. However, none of the available studies was adequately designed to answer this question. This Review discusses major shortcomings in those studies, such as population dissimilarities, hypothyroid state classification and misclassification, the inclusion of nonthyroidal illness, drug interference from concurrent therapies, serious comorbidities (for example, cardiovascular disease), differences in duration of follow-up and the number of levothyroxine-treated individuals. Taken together, the data exhibit little evidence of systematic bias and no strong scientific proof of increased mortality related to either subclinical or overt hypothyroidism. Future studies, however, should take the above-mentioned shortcomings and potential genetic confounding into consideration. 相似文献
109.
Eszter Vojcek V. Anna Gyarmathy Rozsa Graf Anna M. Laszlo Laszlo Ablonczy Zsolt Prodan Istvan Seri 《Congenital heart disease》2022,17(4):447-461
Objective: Neonates with congenital heart disease (CHD) and perinatal stroke have high mortality and survivors are at risk for poor long-term neurodevelopmental outcome. The aim of this study was to assess the risk factors and outcome of neonates with both CHD and MRI-confirmed perinatal stroke (Study Group) and compare those to the risk factors and outcome of infants matched for CHD without stroke (Control-1) and of infants matched for MRI-confirmed stroke without CHD (Control-2). Methods: We conducted a population-based case-control study enrolling 28 term neonates with CHD and MRI-confirmed acute perinatal stroke born between 2007–2017 in the Central-Hungarian Region. Each of the control groups included 56 infants. The Bayley Scales of Infant Development-II, the Brunet-Lézine test and the Binet Intelligence scales-V were used for neurodevelopmental follow-up at a median age of 61 months. Results: Mortality was highest in the Study Group (25% compared to 5% and 2%, respectively, p = 0.001). Adverse neurodevelopmental outcome was prevalent in the Study (53%) and Control-2 Groups (52%, p = 0.03). Significantly different parameters among the three groups included Apgar scores, mode of delivery, gestational age at birth, cardiac interventions and twin pregnancy. In a multivariable regression analysis adjusted for clinically relevant parameters, patients in the Study Group had significantly higher odds for mortality compared to patients in the Control-1 Group (OR: 6.5 95% CI: 1.1–39.4). Conclusions: Neonates with perinatal stroke and CHD are at a higher risk for dying compared to neonates with CHD without stroke. In addition, the stroke-associated direct insult to the brain likely plays an important role in the development of neurodevelopmental morbidity in these patients. 相似文献
110.
Angelika Varga Agnes Jenes Timothy H. Marczylo Joao Sousa-Valente Jie Chen Jonothan Austin Srikumaran Selvarajah Fabiana Piscitelli Anna P. Andreou Anthony H. Taylor Fiona Kyle Mohammed Yaqoob Sue Brain John P. M. White Laszlo Csernoch Vincenzo Di Marzo Laki Buluwela Istvan Nagy 《Pflügers Archiv : European journal of physiology》2014,466(7):1421-1435
The endogenous lipid agent N-arachidonoylethanolamine (anandamide), among other effects, has been shown to be involved in nociceptive processing both in the central and peripheral nervous systems. Anandamide is thought to be synthesised by several enzymatic pathways both in a Ca2+-sensitive and Ca2+-insensitive manner, and rat primary sensory neurons produce anandamide. Here, we show for the first time, that cultured rat primary sensory neurons express at least four of the five known Ca2+-insensitive enzymes implicated in the synthesis of anandamide, and that application of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-arachidonoyl, the common substrate of the anandamide-synthesising pathways, results in anandamide production which is not changed by the removal of extracellular Ca2+. We also show that anandamide, which has been synthesised in primary sensory neurons following the application of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-arachidonoyl induces a transient receptor potential vanilloid type 1 ion channel-mediated excitatory effect that is not inhibited by concomitant activation of the cannabinoid type 1 receptor. Finally, we show that sub-populations of transient receptor potential vanilloid type 1 ion channel-expressing primary sensory neurons also express some of the putative Ca2+-insensitive anandamide-synthesising enzymes. Together, these findings indicate that anandamide synthesised by primary sensory neuron via a Ca2+-insensitive manner has an excitatory rather than an inhibitory role in primary sensory neurons and that excitation is mediated predominantly through autocrine signalling. Regulation of the activity of the Ca2+-insensitive anandamide-synthesising enzymes in these neurons may be capable of regulating the activity of these cells, with potential relevance to controlling nociceptive processing. 相似文献